Research by Tuersun and Bei has emphasized that RBMX is a significant prognostic biomarker in various cancers, including esophageal cancer, where its expression correlates with tumor progression and poor clinical outcomes (79, 80). This evidence concerns the gene RBMX and neoplasm.